Patient advocacy is most effective when it is grounded in evidence rather than personal testimony alone. Drawing on her dual experience as a clinical scientist and a long-standing leader in the rare tumour syndrome community, she shows how patient organisations can generate and use data such as registries, surveys and patient-reported outcomes to strengthen their case. Evidence only creates change when it is translated into a clear, shared language that clinicians, researchers, regulators and industry can act on. Practical examples show how structured partnerships, including with pharmaceutical companies and European Reference Networks, can turn patient insights into better guidelines, research priorities and access to care. The neurofibromatosis community needs a call to action to involve patients partners in research and policy, and to build the evidence base needed for collective action.